This work was supported by the Valda and Robert Svendsen Foundation.
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue†
Article first published online: 24 FEB 2010
Copyright © 2010 Wiley Periodicals, Inc.
Head & Neck
Volume 32, Issue 11, pages 1519–1527, November 2010
How to Cite
Pederson, A. W., Haraf, D. J., Witt, M.-E., Stenson, K. M., Vokes, E. E., Blair, E. A. and Salama, J. K. (2010), Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. Head Neck, 32: 1519–1527. doi: 10.1002/hed.21360
- Issue published online: 24 FEB 2010
- Article first published online: 24 FEB 2010
- Manuscript Accepted: 24 NOV 2009
- Valda and Robert Svendsen Foundation
- base of tongue cancer;
- induction chemotherapy;
- organ preservation
Our aim was to report the outcomes of base of tongue cancers treated with chemoradiotherapy.
Between 1990 and 2004, 127 patients with stage III or IV base of tongue cancer were treated with chemoradiotherapy on protocol. Indications included nodal involvement, T3/T4 tumors, positive margins, those patients refusing surgery, or were medically inoperable. The most common regimen was paclitaxel (100 mg/m2 on day 1), infusional 5-fluorouracil (600 mg/m2/day × 5 days), hydroxyurea (500 mg prescribed orally [PO] 2 × daily [BID]), and 1.5 Gy twice daily irradiation followed by a 9-day break without treatment.
Median follow-up was 51 months. The median dose to gross tumor was 72.5 Gy (range, 40–75.5 Gy). Five-year locoregional progression-free survival, overall survival, and disease-free survival was 87.0%, 58.2%, and 46.0%, respectively.
Concurrent chemoradiotherapy results in promising locoregional control for base of tongue cancer. As distant relapse was common, further investigation of systemic therapy with novel agents may be warranted. © 2010 Wiley Periodicals, Inc. Head Neck, 2010